摘要
在真核生物中被发现的钠钾泵(Na +/ K + ATP酶)被发现在高等真核生物中是维持细胞离子的水泵和渗透压平衡的关键的跨膜蛋白复合物。最近发现其被认为重要的一种传感器和/或信号分子,并且这种信号分子也是维持蛋白质与蛋白质之间相互作用的一种复合物,不过Na +/ K + ATP酶抑制剂最突出的药理作用是在病理条件下增加心肌的收缩力,如充血性心力衰竭。因此,Na +/ K + ATP酶作为调节剂,比如说地高辛已获得监管部门的同意,自1975年以来被广泛用于心力衰竭的治疗。从早期的观察中开始发现在服用了地高辛的心脏病患者癌症的发病率降低了,最近的流行病学和其他研究已经巩固了的Na +/ K + ATP酶抑制剂在前列腺癌,乳腺癌,肺癌或白血病中具有的抗癌潜力。更重要的是,最近一系列新的药理实验优化得到的Na +/ K + ATP酶抑制剂已经在多个临床实验中表明有很强的抗癌活性,并达到了早期临床实验效果。总之,这些结果表明,Na+ / K + ATP酶是一种新兴的癌症靶细胞,并且值得进一步调查。在这次审查中,我们总结了这种酶的主要功能特性,这对肿瘤细胞的选择性有很强的针对性,查看最突出的化学类的Na +/ K + ATP酶抑制剂,并分析其下游感受器。此外我们将整体讨论这些候选药物对于癌症的治疗的发展前景。
关键词: Bufadienolides,蟾蜍灵,癌症治疗,强心苷,强心类固醇,地高辛,istaroxime,Na +/ K + ATP酶,钠钾ATP酶,Na +/ K + ATP酶甾体抑制剂
Current Drug Targets
Title:Na+/K+ ATPase Inhibitors in Cancer
Volume: 15 Issue: 10
Author(s): Konstantinos Alevizopoulos, Theodora Calogeropoulou, Florian Lang and Christos Stournaras
Affiliation:
关键词: Bufadienolides,蟾蜍灵,癌症治疗,强心苷,强心类固醇,地高辛,istaroxime,Na +/ K + ATP酶,钠钾ATP酶,Na +/ K + ATP酶甾体抑制剂
摘要: Sodium potassium pump (Na+/K+ ATPase) is a transmembrane protein complex found in all higher eukaryotes acting as a key energy-consuming pump maintaining ionic and osmotic balance in cells. Recently recognized as an important transducer and/or integrator of various signals as well as a protein-protein interaction scaffold forming receptor complexes with signaling properties, the most prominent pharmacological role of Na+/K+ ATPase inhibitors is the increase of myocardial contractility in pathologic conditions such as congestive heart failure. Consequently, modulators of Na+/K+ ATPase such as digoxin have been approved by regulatory authorities and are widely used in the treatment of cardiac failure since 1975. Initiating from early observations of reduction of cancer incidence in cardiac patients taking digoxin, recent epidemiological and other studies have consolidated the anti-cancer potential of Na+/K+ ATPase inhibitors in indications such as prostate, breast, lung cancer or leukemia. More importantly, a new series of pharmacologically optimized Na+/K+ ATPase inhibitors has recently shown strong anti-cancer activities in multiple preclinical assays and have reached early clinical trials. Altogether, these results suggest that Na+/K+ ATPase is an emerging cancer target that merits further investigation. In this review, we summarize key functional properties of the enzyme that are highly relevant for cancer cell selectivity, review the most prominent chemical classes of Na+/K+ ATPase inhibitors and analyze their downstream effectors. Moreover, we discuss overall development prospects of these candidate drugs on their way to becoming new effective treatments of cancer in patients.
Export Options
About this article
Cite this article as:
Alevizopoulos Konstantinos, Calogeropoulou Theodora, Lang Florian and Stournaras Christos, Na+/K+ ATPase Inhibitors in Cancer, Current Drug Targets 2014; 15 (10) . https://dx.doi.org/10.2174/1389450115666140908125025
DOI https://dx.doi.org/10.2174/1389450115666140908125025 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Polypharmacology in Precision Oncology: Current Applications and Future Prospects
Current Pharmaceutical Design Biotechnological Production of Taxol and Related Taxoids: Current State and Prospects
Anti-Cancer Agents in Medicinal Chemistry Novel Genetic and Peptide-Based Strategies Targeting the Bcl-2 Family, an Update
Recent Patents on DNA & Gene Sequences MDR Reversal by Deprenylated Tetracyclic and Hexacyclic Analogues of N-Acetylardeemin: Confirmation of the Ardeemin Pharmacophore
Letters in Drug Design & Discovery Asthma, Allergy and Chemokines
Current Drug Targets PEGylation: An Overview and Recent Advances Reported in the Patent Literature
Recent Patents on Chemical Engineering Intracellular Routing of Cytotoxic Pancreatic-Type Ribonucleases
Current Pharmaceutical Biotechnology Aminophosphonate Metal Complexes of Biomedical Potential
Current Medicinal Chemistry Bortezomib and Arsenious Acid Synergistically Inhibit HL-60 Cells Viability in vitro and in vivo
Current Signal Transduction Therapy Combining Anti-Epidermal Growth Factor Receptor (EGFR) and Anti-Angiogenic Strategies in Advanced NSCLC: We Should have Known Better...
Current Pharmaceutical Design Synthesis and Preliminarily Cytotoxicity to A549, HCT116 and MCF-7 Cell Lines of thieno[2,3-d]pyrimidine Derivatives Containing Isoxazole Moiety
Letters in Drug Design & Discovery Palmitoylethanolamide in Homeostatic and Traumatic Central Nervous System Injuries
CNS & Neurological Disorders - Drug Targets Computational Peptidology: A New and Promising Approach to Therapeutic Peptide Design
Current Medicinal Chemistry MicroRNA-21 as Therapeutic Target in Cancer and Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Novel Aminopeptidase N Inhibitors with Improved Antitumor Activities
Letters in Drug Design & Discovery FDG-PET/CT for Systemic Infections
Current Molecular Imaging (Discontinued) Aptamers as Innovative Diagnostic and Therapeutic Agents in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Oncolytic Coxsackievirus and the Mechanisms of its Effects on Cancer: A Narrative Review
Current Cancer Therapy Reviews Evaluation of Fourteen Aurone Derivatives as Potential Anti-Cancer Agents
Current Pharmaceutical Biotechnology The Use of Conformational Restriction in Medicinal Chemistry
Current Topics in Medicinal Chemistry